Argenx Se ARGX
NASDAQ ARGX
$1,033.15 -20.31 (-1.93%)
At close: Sep 4, 2026 · 4:00 PM EDT

Argenx Se (ARGX) Income from Continuing Operations (2016 - 2026)

Argenx Se's (ARGX) quarterly Income from Continuing Operations came in at $601.0 million in Q2 2026, up 82.99% on a YoY basis from $328.4 million in Q2 2025, and up 20.44% quarter-over-quarter from $499.0 million in Q1 2026.

Analysis

Argenx Se (ARGX) Income from Continuing Operations (2016 - 2026) Analysis & Trends

Argenx Se (ARGX) has reported Income from Continuing Operations for 11 consecutive years, with $601.0 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Income from Continuing Operations rose 82.99% year-over-year to $601.0 million; the trailing twelve-month figure through Jun 2026 stood at $1.8 billion (up 3935.77% YoY), and the FY2025 full-year result was $1.3 billion, up 290.92% from the prior year.
  • Income from Continuing Operations climbed to $601.0 million in Q2 2026 per ARGX's latest filing, from $499.0 million in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at $601.0 million in Q2 2026 and bottomed at -$603.8 million in Q4 2024.
  • Historically, Income from Continuing Operations has averaged $35.4 million across 5 years, with a median of -$51.5 million in 2022.
  • The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations sank 2504.39% in 2024, then surged 656.0% in 2025.
  • Over 5 years, Income from Continuing Operations stood at -$43.9 million in 2022, then surged by 47.14% to -$23.2 million in 2023, then tumbled by 2504.39% to -$603.8 million in 2024, then surged by 145.32% to $273.6 million in 2025, then soared by 119.63% to $601.0 million in 2026.
  • According to Business Quant data, Income from Continuing Operations over the past three periods registered $601.0 million, $499.0 million, and $273.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Amgen 236.37 Bn 222.38 Bn 7.24 Bn 2.38 Bn
2 Gilead Sciences 187.38 Bn 184.12 Bn 6.22 Bn -10.50 Bn
3 Vertex Pharmaceuticals 138.36 Bn 130.51 Bn 2.84 Bn 1.10 Bn
4 Regeneron Pharmaceuticals 85.09 Bn 77.10 Bn 3.93 Bn 1.30 Bn
5 Argenx Se 63.93 Bn 58.75 Bn 1.37 Bn 601.00 Mn
6 Moderna 58.07 Bn 52.94 Bn 52.00 Mn -782.00 Mn
7 Alnylam Pharmaceuticals 35.59 Bn 32.28 Bn 992.69 Mn 164.49 Mn
8 Biogen 32.63 Bn 31.34 Bn 1.96 Bn 97.50 Mn
9 Insmed 27.57 Bn 26.41 Bn 358.27 Mn -13.27 Mn
10 BioNTech SE 26.24 Bn 12.58 Bn 10.00 Mn -1.04 Bn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 601.00 Mn
Mar 31, 2026 499.00 Mn
Dec 31, 2025 273.64 Mn
Sep 30, 2025 427.85 Mn
Jun 30, 2025 328.44 Mn
Mar 31, 2025 235.36 Mn
Dec 31, 2024 -603.80 Mn
Sep 30, 2024 84.64 Mn
Jun 30, 2024 -59.07 Mn
Mar 31, 2024 -87.10 Mn
Dec 31, 2023 -23.18 Mn
Sep 30, 2023 -93.92 Mn
Jun 30, 2023 -73.35 Mn
Mar 31, 2023 -123.49 Mn
Dec 31, 2022 -43.86 Mn
Sep 30, 2022 -247.01 Mn
Jun 30, 2022 -225.21 Mn
Mar 31, 2022 -232.96 Mn
Dec 31, 2021 -251.94 Mn
Sep 30, 2021 -228.12 Mn